APO Research
Talk to an analyst

APO RESEARCH · REPORT

Bispecific Antibody Drug

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Bispecific Antibody Drug Market Analysis and Forecast 2026-2032

2 January 2026201 pages

Choose your research edition.

Industry ResearchBispecific Antibody Drug Industry Research Report 2026126 pages · $2,950 USDIndustry Growth & TrendsGlobal Bispecific Antibody Drug Industry Growth and Trends Forecast to 2032110 pages · $3,450 USDMarket StructureGlobal Bispecific Antibody Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Bispecific Antibody Drug Market Outlook and Growth Opportunities 2026204 pages · $4,250 USDMarket Analysis & ForecastGlobal Bispecific Antibody Drug Market Analysis and Forecast 2026-2032201 pages · $4,950 USD

Market perspective

The global Bispecific Antibody Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Bispecific Antibody Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Bispecific Antibody Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Bispecific Antibody Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Bispecific Antibody Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Bispecific Antibody Drug include Affimed, Akeso, Alphamab, BeiGene, Genmab, Immunocore Limited, Lindis Biotech, MacroGenics and Xencor, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Bispecific Antibody Drug, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Bispecific Antibody Drug, also provides the revenue of main regions and countries. Of the upcoming market potential for Bispecific Antibody Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Bispecific Antibody Drug revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Bispecific Antibody Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Bispecific Antibody Drug revenue, projected growth trends, production technology, application and end-user industry.

Bispecific Antibody Drug Segment by Company

Affimed

Akeso

Alphamab

BeiGene

Genmab

Immunocore Limited

Lindis Biotech

MacroGenics

Xencor

AstraZeneca

Abbvie

Amgen

Pfizer

Roche

Merck

Johnson & Johnson

Sanofi

Bispecific Antibody Drug Segment by Type

Fragment-Based

IgG-Based

Bispecific Antibody Drug Segment by Application

Cancer

Haemophilia

Other Diseases

Bispecific Antibody Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Bispecific Antibody Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Bispecific Antibody Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Bispecific Antibody Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Bispecific Antibody Drug in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Bispecific Antibody Drug company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Bispecific Antibody Drug revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Bispecific Antibody Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Fragment-Based Major Player Table 3. IgG-Based Major Player Table 4. Global Bispecific Antibody Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Cancer Major Player Table 6. Haemophilia Major Player Table 7. Other Diseases Major Player Table 8. Bispecific Antibody Drug Industry Trends Table 9. Bispecific Antibody Drug Industry Drivers Table 10. Bispecific Antibody Drug Industry Opportunities and Challenges Table 11. Bispecific Antibody Drug Industry Restraints Table 12. Global Bispecific Antibody Drug Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 13. Global Bispecific Antibody Drug Market Size by Region (2021-2026) & (US$ Million) Table 14. Global Bispecific Antibody Drug Market Share by Region (2021-2026) Table 15. Global Bispecific Antibody Drug Market Size by Region (2027-2032) & (US$ Million) Table 16. Global Bispecific Antibody Drug Market Share by Region (2027-2032) Table 17. Global Bispecific Antibody Drug Revenue by Players (US$ Million) & (2021-2026) Table 18. Global Bispecific Antibody Drug Revenue Market Share by Players (2021-2026) Table 19. Global Bispecific Antibody Drug Key Players Ranking, 2024 VS 2025 VS 2026 Table 20. Global Bispecific Antibody Drug Key Players Headquarters & Area Served Table 21. Global Bispecific Antibody Drug Players, Product Type & Application Table 22. Global Bispecific Antibody Drug Players Establishment Date Table 23. Global Players Market Concentration Ratio (CR5 and HHI) Table 24. Global Bispecific Antibody Drug by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 25. Global Bispecific Antibody Drug Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Bispecific Antibody Drug Revenue by Type (2021-2026) & (US$ Million) Table 27. Global Bispecific Antibody Drug Revenue by Type (2027-2032) & (US$ Million) Table 28. Global Bispecific Antibody Drug Revenue Market Share by Type (2021-2026) Table 29. Global Bispecific Antibody Drug Revenue Market Share by Type (2027-2032) Table 30. Global Bispecific Antibody Drug Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Bispecific Antibody Drug Revenue by Application (2021-2026) & (US$ Million) Table 32. Global Bispecific Antibody Drug Revenue by Application (2027-2032) & (US$ Million) Table 33. Global Bispecific Antibody Drug Revenue Market Share by Application (2021-2026) Table 34. Global Bispecific Antibody Drug Revenue Market Share by Application (2027-2032) Table 35. Affimed Company Information Table 36. Affimed Business Overview Table 37. Affimed Bispecific Antibody Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Affimed Bispecific Antibody Drug Product Portfolio Table 39. Affimed Recent Development Table 40. Akeso Company Information Table 41. Akeso Business Overview Table 42. Akeso Bispecific Antibody Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Akeso Bispecific Antibody Drug Product Portfolio Table 44. Akeso Recent Development Table 45. Alphamab Company Information Table 46. Alphamab Business Overview Table 47. Alphamab Bispecific Antibody Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Alphamab Bispecific Antibody Drug Product Portfolio Table 49. Alphamab Recent Development Table 50. BeiGene Company Information Table 51. BeiGene Business Overview Table 52. BeiGene Bispecific Antibody Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. BeiGene Bispecific Antibody Drug Product Portfolio Table 54. BeiGene Recent Development Table 55. Genmab Company Information Table 56. Genmab Business Overview Table 57. Genmab Bispecific Antibody Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Genmab Bispecific Antibody Drug Product Portfolio Table 59. Genmab Recent Development Table 60. Immunocore Limited Company Information Table 61. Immunocore Limited Business Overview Table 62. Immunocore Limited Bispecific Antibody Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. Immunocore Limited Bispecific Antibody Drug Product Portfolio Table 64. Immunocore Limited Recent Development Table 65. Lindis Biotech Company Information Table 66. Lindis Biotech Business Overview Table 67. Lindis Biotech Bispecific Antibody Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. Lindis Biotech Bispecific Antibody Drug Product Portfolio Table 69. Lindis Biotech Recent Development Table 70. MacroGenics Company Information Table 71. MacroGenics Business Overview Table 72. MacroGenics Bispecific Antibody Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. MacroGenics Bispecific Antibody Drug Product Portfolio Table 74. MacroGenics Recent Development Table 75. Xencor Company Information Table 76. Xencor Business Overview Table 77. Xencor Bispecific Antibody Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. Xencor Bispecific Antibody Drug Product Portfolio Table 79. Xencor Recent Development Table 80. AstraZeneca Company Information Table 81. AstraZeneca Business Overview Table 82. AstraZeneca Bispecific Antibody Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 83. AstraZeneca Bispecific Antibody Drug Product Portfolio Table 84. AstraZeneca Recent Development Table 85. Abbvie Company Information Table 86. Abbvie Business Overview Table 87. Abbvie Bispecific Antibody Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. Abbvie Bispecific Antibody Drug Product Portfolio Table 89. Abbvie Recent Development Table 90. Amgen Company Information Table 91. Amgen Business Overview Table 92. Amgen Bispecific Antibody Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Amgen Bispecific Antibody Drug Product Portfolio Table 94. Amgen Recent Development Table 95. Pfizer Company Information Table 96. Pfizer Business Overview Table 97. Pfizer Bispecific Antibody Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Pfizer Bispecific Antibody Drug Product Portfolio Table 99. Pfizer Recent Development Table 100. Roche Company Information Table 101. Roche Business Overview Table 102. Roche Bispecific Antibody Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Roche Bispecific Antibody Drug Product Portfolio Table 104. Roche Recent Development Table 105. Merck Company Information Table 106. Merck Business Overview Table 107. Merck Bispecific Antibody Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. Merck Bispecific Antibody Drug Product Portfolio Table 109. Merck Recent Development Table 110. Johnson & Johnson Company Information Table 111. Johnson & Johnson Business Overview Table 112. Johnson & Johnson Bispecific Antibody Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. Johnson & Johnson Bispecific Antibody Drug Product Portfolio Table 114. Johnson & Johnson Recent Development Table 115. Sanofi Company Information Table 116. Sanofi Business Overview Table 117. Sanofi Bispecific Antibody Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 118. Sanofi Bispecific Antibody Drug Product Portfolio Table 119. Sanofi Recent Development Table 120. North America Bispecific Antibody Drug Revenue by Type (2021-2026) & (US$ Million) Table 121. North America Bispecific Antibody Drug Revenue by Type (2027-2032) & (US$ Million) Table 122. North America Bispecific Antibody Drug Revenue by Application (2021-2026) & (US$ Million) Table 123. North America Bispecific Antibody Drug Revenue by Application (2027-2032) & (US$ Million) Table 124. North America Bispecific Antibody Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 125. North America Bispecific Antibody Drug Revenue by Country (2021-2026) & (US$ Million) Table 126. North America Bispecific Antibody Drug Revenue by Country (US$ Million) & (2027-2032) Table 127. Europe Bispecific Antibody Drug Revenue by Type (2021-2026) & (US$ Million) Table 128. Europe Bispecific Antibody Drug Revenue by Type (2027-2032) & (US$ Million) Table 129. Europe Bispecific Antibody Drug Revenue by Application (2021-2026) & (US$ Million) Table 130. Europe Bispecific Antibody Drug Revenue by Application (2027-2032) & (US$ Million) Table 131. Europe Bispecific Antibody Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 132. Europe Bispecific Antibody Drug Revenue by Country (2021-2026) & (US$ Million) Table 133. Europe Bispecific Antibody Drug Revenue by Country (US$ Million) & (2027-2032) Table 134. China Bispecific Antibody Drug Revenue by Type (2021-2026) & (US$ Million) Table 135. China Bispecific Antibody Drug Revenue by Type (2027-2032) & (US$ Million) Table 136. China Bispecific Antibody Drug Revenue by Application (2021-2026) & (US$ Million) Table 137. China Bispecific Antibody Drug Revenue by Application (2027-2032) & (US$ Million) Table 138. Asia Bispecific Antibody Drug Revenue by Type (2021-2026) & (US$ Million) Table 139. Asia Bispecific Antibody Drug Revenue by Type (2027-2032) & (US$ Million) Table 140. Asia Bispecific Antibody Drug Revenue by Application (2021-2026) & (US$ Million) Table 141. Asia Bispecific Antibody Drug Revenue by Application (2027-2032) & (US$ Million) Table 142. Asia Bispecific Antibody Drug Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 143. Asia Bispecific Antibody Drug Revenue by Region (US$ Million) & (2021-2026) Table 144. Asia Bispecific Antibody Drug Revenue by Region (US$ Million) & (2027-2032) Table 145. SAMEA Bispecific Antibody Drug Revenue by Type (2021-2026) & (US$ Million) Table 146. SAMEA Bispecific Antibody Drug Revenue by Type (2027-2032) & (US$ Million) Table 147. SAMEA Bispecific Antibody Drug Revenue by Application (2021-2026) & (US$ Million) Table 148. SAMEA Bispecific Antibody Drug Revenue by Application (2027-2032) & (US$ Million) Table 149. SAMEA Bispecific Antibody Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 150. SAMEA Bispecific Antibody Drug Revenue by Country (2021-2026) & (US$ Million) Table 151. SAMEA Bispecific Antibody Drug Revenue by Country (US$ Million) & (2027-2032) Table 152. Research Programs/Design for This Report Table 153. Authors List of This Report Table 154. Secondary Sources Table 155. Primary Sources List of Figures Figure 1. Bispecific Antibody Drug Image Figure 2. Global Bispecific Antibody Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Bispecific Antibody Drug Market Size Share 2021 VS 2025 VS 2032 Figure 4. Fragment-Based Image Figure 5. IgG-Based Image Figure 6. Global Bispecific Antibody Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Bispecific Antibody Drug Market Size Share 2021 VS 2025 VS 2032 Figure 8. Cancer Image Figure 9. Haemophilia Image Figure 10. Other Diseases Image Figure 11. Global Bispecific Antibody Drug Market Size (US$ Million) & (2021-2032) Figure 12. Global Bispecific Antibody Drug Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Bispecific Antibody Drug Market Share by Region: 2021 VS 2025 VS 2032 Figure 14. Global Bispecific Antibody Drug Players Revenue Share Top 10 and Top 5 in 2025 Figure 15. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 16. Global Bispecific Antibody Drug Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Bispecific Antibody Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Bispecific Antibody Drug Revenue Market Share by Type (2021-2032) Figure 19. Global Bispecific Antibody Drug Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Bispecific Antibody Drug Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 21. Global Bispecific Antibody Drug Revenue Market Share by Application (2021-2032) Figure 22. North America Bispecific Antibody Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 23. North America Bispecific Antibody Drug Revenue Share by Type (2021-2032) Figure 24. North America Bispecific Antibody Drug Revenue Share by Application (2021-2032) Figure 25. North America Bispecific Antibody Drug Revenue Share by Country (2021-2032) Figure 26. United States Bispecific Antibody Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Canada Bispecific Antibody Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Mexico Bispecific Antibody Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Europe Bispecific Antibody Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 30. Europe Bispecific Antibody Drug Revenue Share by Type (2021-2032) Figure 31. Europe Bispecific Antibody Drug Revenue Share by Application (2021-2032) Figure 32. Europe Bispecific Antibody Drug Revenue Share by Country (2021-2032) Figure 33. Germany Bispecific Antibody Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. France Bispecific Antibody Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. U.K. Bispecific Antibody Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Italy Bispecific Antibody Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Spain Bispecific Antibody Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Russia Bispecific Antibody Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Netherlands Bispecific Antibody Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Nordic Countries Bispecific Antibody Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. China Bispecific Antibody Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 42. China Bispecific Antibody Drug Revenue Share by Type (2021-2032) Figure 43. China Bispecific Antibody Drug Revenue Share by Application (2021-2032) Figure 44. Asia Bispecific Antibody Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. Asia Bispecific Antibody Drug Revenue Share by Type (2021-2032) Figure 46. Asia Bispecific Antibody Drug Revenue Share by Application (2021-2032) Figure 47. Asia Bispecific Antibody Drug Revenue Share by Region (2021-2032) Figure 48. Japan Bispecific Antibody Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. South Korea Bispecific Antibody Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. India Bispecific Antibody Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Australia Bispecific Antibody Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Taiwan Bispecific Antibody Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Southeast Asia Bispecific Antibody Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. SAMEA Bispecific Antibody Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 55. SAMEA Bispecific Antibody Drug Revenue Share by Type (2021-2032) Figure 56. SAMEA Bispecific Antibody Drug Revenue Share by Application (2021-2032) Figure 57. SAMEA Bispecific Antibody Drug Revenue Share by Country (2021-2032) Figure 58. Brazil Bispecific Antibody Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Argentina Bispecific Antibody Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Chile Bispecific Antibody Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Colombia Bispecific Antibody Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Peru Bispecific Antibody Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Saudi Arabia Bispecific Antibody Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Israel Bispecific Antibody Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. UAE Bispecific Antibody Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Turkey Bispecific Antibody Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Iran Bispecific Antibody Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Egypt Bispecific Antibody Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Fragment-Based
  • IgG-Based
Applications
  • Cancer
  • Haemophilia
  • Other Diseases
Companies covered
  • Affimed
  • Akeso
  • Alphamab
  • BeiGene
  • Genmab
  • Immunocore Limited
  • Lindis Biotech
  • MacroGenics
  • Xencor
  • AstraZeneca
  • Abbvie
  • Amgen
  • Pfizer
  • Roche
  • Merck
  • Johnson & Johnson
  • Sanofi

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Bispecific Antibody Drug Market by Type
  3. 1.2.1 Global Bispecific Antibody Drug Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Fragment-Based
  5. 1.2.3 IgG-Based
  6. 1.3 Bispecific Antibody Drug Market by Application
  7. 1.3.1 Global Bispecific Antibody Drug Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Cancer
  9. 1.3.3 Haemophilia
  10. 1.3.4 Other Diseases
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Bispecific Antibody Drug Market Dynamics
  1. 2.1 Bispecific Antibody Drug Industry Trends
  2. 2.2 Bispecific Antibody Drug Industry Drivers
  3. 2.3 Bispecific Antibody Drug Industry Opportunities and Challenges
  4. 2.4 Bispecific Antibody Drug Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Bispecific Antibody Drug Market Perspective (2021-2032)
  2. 3.2 Global Bispecific Antibody Drug Growth Trends by Region
  3. 3.2.1 Global Bispecific Antibody Drug Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Bispecific Antibody Drug Market Size by Region (2021-2026)
  5. 3.2.3 Global Bispecific Antibody Drug Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Bispecific Antibody Drug Revenue by Players
  2. 4.1.1 Global Bispecific Antibody Drug Revenue by Players (2021-2026)
  3. 4.1.2 Global Bispecific Antibody Drug Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Bispecific Antibody Drug Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Bispecific Antibody Drug Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Bispecific Antibody Drug Key Players Headquarters & Area Served
  7. 4.4 Global Bispecific Antibody Drug Players, Product Type & Application
  8. 4.5 Global Bispecific Antibody Drug Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Bispecific Antibody Drug Market CR5 and HHI
  11. 4.6.3 2025 Bispecific Antibody Drug Tier 1, Tier 2, and Tier 3
5 Bispecific Antibody Drug Market Size by Type
  1. 5.1 Global Bispecific Antibody Drug Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Bispecific Antibody Drug Revenue by Type (2021-2032)
  3. 5.3 Global Bispecific Antibody Drug Revenue Market Share by Type (2021-2032)
6 Bispecific Antibody Drug Market Size by Application
  1. 6.1 Global Bispecific Antibody Drug Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Bispecific Antibody Drug Revenue by Application (2021-2032)
  3. 6.3 Global Bispecific Antibody Drug Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Affimed
  2. 7.1.1 Affimed Company Information
  3. 7.1.2 Affimed Business Overview
  4. 7.1.3 Affimed Bispecific Antibody Drug Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Affimed Bispecific Antibody Drug Product Portfolio
  6. 7.1.5 Affimed Recent Developments
  7. 7.2 Akeso
  8. 7.2.1 Akeso Company Information
  9. 7.2.2 Akeso Business Overview
  10. 7.2.3 Akeso Bispecific Antibody Drug Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Akeso Bispecific Antibody Drug Product Portfolio
  12. 7.2.5 Akeso Recent Developments
  13. 7.3 Alphamab
  14. 7.3.1 Alphamab Company Information
  15. 7.3.2 Alphamab Business Overview
  16. 7.3.3 Alphamab Bispecific Antibody Drug Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Alphamab Bispecific Antibody Drug Product Portfolio
  18. 7.3.5 Alphamab Recent Developments
  19. 7.4 BeiGene
  20. 7.4.1 BeiGene Company Information
  21. 7.4.2 BeiGene Business Overview
  22. 7.4.3 BeiGene Bispecific Antibody Drug Revenue and Gross Margin (2021-2026)
  23. 7.4.4 BeiGene Bispecific Antibody Drug Product Portfolio
  24. 7.4.5 BeiGene Recent Developments
  25. 7.5 Genmab
  26. 7.5.1 Genmab Company Information
  27. 7.5.2 Genmab Business Overview
  28. 7.5.3 Genmab Bispecific Antibody Drug Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Genmab Bispecific Antibody Drug Product Portfolio
  30. 7.5.5 Genmab Recent Developments
  31. 7.6 Immunocore Limited
  32. 7.6.1 Immunocore Limited Company Information
  33. 7.6.2 Immunocore Limited Business Overview
  34. 7.6.3 Immunocore Limited Bispecific Antibody Drug Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Immunocore Limited Bispecific Antibody Drug Product Portfolio
  36. 7.6.5 Immunocore Limited Recent Developments
  37. 7.7 Lindis Biotech
  38. 7.7.1 Lindis Biotech Company Information
  39. 7.7.2 Lindis Biotech Business Overview
  40. 7.7.3 Lindis Biotech Bispecific Antibody Drug Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Lindis Biotech Bispecific Antibody Drug Product Portfolio
  42. 7.7.5 Lindis Biotech Recent Developments
  43. 7.8 MacroGenics
  44. 7.8.1 MacroGenics Company Information
  45. 7.8.2 MacroGenics Business Overview
  46. 7.8.3 MacroGenics Bispecific Antibody Drug Revenue and Gross Margin (2021-2026)
  47. 7.8.4 MacroGenics Bispecific Antibody Drug Product Portfolio
  48. 7.8.5 MacroGenics Recent Developments
  49. 7.9 Xencor
  50. 7.9.1 Xencor Company Information
  51. 7.9.2 Xencor Business Overview
  52. 7.9.3 Xencor Bispecific Antibody Drug Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Xencor Bispecific Antibody Drug Product Portfolio
  54. 7.9.5 Xencor Recent Developments
  55. 7.10 AstraZeneca
  56. 7.10.1 AstraZeneca Company Information
  57. 7.10.2 AstraZeneca Business Overview
  58. 7.10.3 AstraZeneca Bispecific Antibody Drug Revenue and Gross Margin (2021-2026)
  59. 7.10.4 AstraZeneca Bispecific Antibody Drug Product Portfolio
  60. 7.10.5 AstraZeneca Recent Developments
  61. 7.11 Abbvie
  62. 7.11.1 Abbvie Company Information
  63. 7.11.2 Abbvie Business Overview
  64. 7.11.3 Abbvie Bispecific Antibody Drug Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Abbvie Bispecific Antibody Drug Product Portfolio
  66. 7.11.5 Abbvie Recent Developments
  67. 7.12 Amgen
  68. 7.12.1 Amgen Company Information
  69. 7.12.2 Amgen Business Overview
  70. 7.12.3 Amgen Bispecific Antibody Drug Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Amgen Bispecific Antibody Drug Product Portfolio
  72. 7.12.5 Amgen Recent Developments
  73. 7.13 Pfizer
  74. 7.13.1 Pfizer Company Information
  75. 7.13.2 Pfizer Business Overview
  76. 7.13.3 Pfizer Bispecific Antibody Drug Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Pfizer Bispecific Antibody Drug Product Portfolio
  78. 7.13.5 Pfizer Recent Developments
  79. 7.14 Roche
  80. 7.14.1 Roche Company Information
  81. 7.14.2 Roche Business Overview
  82. 7.14.3 Roche Bispecific Antibody Drug Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Roche Bispecific Antibody Drug Product Portfolio
  84. 7.14.5 Roche Recent Developments
  85. 7.15 Merck
  86. 7.15.1 Merck Company Information
  87. 7.15.2 Merck Business Overview
  88. 7.15.3 Merck Bispecific Antibody Drug Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Merck Bispecific Antibody Drug Product Portfolio
  90. 7.15.5 Merck Recent Developments
  91. 7.16 Johnson & Johnson
  92. 7.16.1 Johnson & Johnson Company Information
  93. 7.16.2 Johnson & Johnson Business Overview
  94. 7.16.3 Johnson & Johnson Bispecific Antibody Drug Revenue and Gross Margin (2021-2026)
  95. 7.16.4 Johnson & Johnson Bispecific Antibody Drug Product Portfolio
  96. 7.16.5 Johnson & Johnson Recent Developments
  97. 7.17 Sanofi
  98. 7.17.1 Sanofi Company Information
  99. 7.17.2 Sanofi Business Overview
  100. 7.17.3 Sanofi Bispecific Antibody Drug Revenue and Gross Margin (2021-2026)
  101. 7.17.4 Sanofi Bispecific Antibody Drug Product Portfolio
  102. 7.17.5 Sanofi Recent Developments
8 North America
  1. 8.1 North America Bispecific Antibody Drug Revenue (2021-2032)
  2. 8.2 North America Bispecific Antibody Drug Revenue by Type (2021-2032)
  3. 8.2.1 North America Bispecific Antibody Drug Revenue by Type (2021-2026)
  4. 8.2.2 North America Bispecific Antibody Drug Revenue by Type (2027-2032)
  5. 8.3 North America Bispecific Antibody Drug Revenue Share by Type (2021-2032)
  6. 8.4 North America Bispecific Antibody Drug Revenue by Application (2021-2032)
  7. 8.4.1 North America Bispecific Antibody Drug Revenue by Application (2021-2026)
  8. 8.4.2 North America Bispecific Antibody Drug Revenue by Application (2027-2032)
  9. 8.5 North America Bispecific Antibody Drug Revenue Share by Application (2021-2032)
  10. 8.6 North America Bispecific Antibody Drug Revenue by Country
  11. 8.6.1 North America Bispecific Antibody Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Bispecific Antibody Drug Revenue by Country (2021-2026)
  13. 8.6.3 North America Bispecific Antibody Drug Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Bispecific Antibody Drug Revenue (2021-2032)
  2. 9.2 Europe Bispecific Antibody Drug Revenue by Type (2021-2032)
  3. 9.2.1 Europe Bispecific Antibody Drug Revenue by Type (2021-2026)
  4. 9.2.2 Europe Bispecific Antibody Drug Revenue by Type (2027-2032)
  5. 9.3 Europe Bispecific Antibody Drug Revenue Share by Type (2021-2032)
  6. 9.4 Europe Bispecific Antibody Drug Revenue by Application (2021-2032)
  7. 9.4.1 Europe Bispecific Antibody Drug Revenue by Application (2021-2026)
  8. 9.4.2 Europe Bispecific Antibody Drug Revenue by Application (2027-2032)
  9. 9.5 Europe Bispecific Antibody Drug Revenue Share by Application (2021-2032)
  10. 9.6 Europe Bispecific Antibody Drug Revenue by Country
  11. 9.6.1 Europe Bispecific Antibody Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Bispecific Antibody Drug Revenue by Country (2021-2026)
  13. 9.6.3 Europe Bispecific Antibody Drug Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China Bispecific Antibody Drug Revenue (2021-2032)
  2. 10.2 China Bispecific Antibody Drug Revenue by Type (2021-2032)
  3. 10.2.1 China Bispecific Antibody Drug Revenue by Type (2021-2026)
  4. 10.2.2 China Bispecific Antibody Drug Revenue by Type (2027-2032)
  5. 10.3 China Bispecific Antibody Drug Revenue Share by Type (2021-2032)
  6. 10.4 China Bispecific Antibody Drug Revenue by Application (2021-2032)
  7. 10.4.1 China Bispecific Antibody Drug Revenue by Application (2021-2026)
  8. 10.4.2 China Bispecific Antibody Drug Revenue by Application (2027-2032)
  9. 10.5 China Bispecific Antibody Drug Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Bispecific Antibody Drug Revenue (2021-2032)
  2. 11.2 Asia Bispecific Antibody Drug Revenue by Type (2021-2032)
  3. 11.2.1 Asia Bispecific Antibody Drug Revenue by Type (2021-2026)
  4. 11.2.2 Asia Bispecific Antibody Drug Revenue by Type (2027-2032)
  5. 11.3 Asia Bispecific Antibody Drug Revenue Share by Type (2021-2032)
  6. 11.4 Asia Bispecific Antibody Drug Revenue by Application (2021-2032)
  7. 11.4.1 Asia Bispecific Antibody Drug Revenue by Application (2021-2026)
  8. 11.4.2 Asia Bispecific Antibody Drug Revenue by Application (2027-2032)
  9. 11.5 Asia Bispecific Antibody Drug Revenue Share by Application (2021-2032)
  10. 11.6 Asia Bispecific Antibody Drug Revenue by Country
  11. 11.6.1 Asia Bispecific Antibody Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Bispecific Antibody Drug Revenue by Country (2021-2026)
  13. 11.6.3 Asia Bispecific Antibody Drug Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Bispecific Antibody Drug Revenue (2021-2032)
  2. 12.2 SAMEA Bispecific Antibody Drug Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Bispecific Antibody Drug Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Bispecific Antibody Drug Revenue by Type (2027-2032)
  5. 12.3 SAMEA Bispecific Antibody Drug Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Bispecific Antibody Drug Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Bispecific Antibody Drug Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Bispecific Antibody Drug Revenue by Application (2027-2032)
  9. 12.5 SAMEA Bispecific Antibody Drug Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Bispecific Antibody Drug Revenue by Country
  11. 12.6.1 SAMEA Bispecific Antibody Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Bispecific Antibody Drug Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Bispecific Antibody Drug Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst